… association between patients’ performance status and the effect of chemotherapy on QOL in
the … with good performance status who receive additional palliative chemotherapy will have …

Purpose A multicenter randomized phase II trial to evaluate two treatment strategies in the
first-line management of advanced non–small-cell lung cancer (NSCLC) patients with a …

… chemotherapy is associated with clinical improvement in a substantial number of patients with
advanced nonsmall cell lung cancer of poor performance status. … , without standard control …

… the use of chemotherapy still unanswered. It is now recognized that chemotherapy improves
… whether these benefits apply to patients with poor performance status (PS). These patients (…

… Treatment with platinum-based combination chemotherapy is considered standard of care
for patients with metastatic NSCLC and performance status (PS) 0–1 since it has been shown …

… toxicity for combination chemotherapy. Based on these data, chemotherapy using the combination
… or vinorelbine, and single agent chemotherapy should remain the standard treatment. …

… use combination chemotherapy regimens, including those containing standard doses of …
PS 2 patients from future trials that employ more toxic combination chemotherapy regimens. …

… have included patients with poor performance status. This study … chemotherapy by patient
performance status and symptoms and how physician characteristics influence chemotherapy …

… Performance status, regardless of what scale was used, is one of the most efficient …
Nevertheless, so far, there are no data showing that our current standard chemotherapy approach is …

… Anti-EGFR monoclonal antibodies are not standard in first-line therapy (we rather use them
… the combination of biologic agents with standard chemotherapy in patients with ECOG PS ≥ …